Current issues in adeno-associated viral vector production

Adeno-associated virus (AAV) is currently one of the most promising systems for human gene therapy. Numerous preclinical studies have documented the excellent safety profile of these vectors along with their impressive performances in their favored target, consisting of highly differentiated postmitotic tissues such as muscle, central nervous system and liver. Clinical trials have been conducted confirming these data, but also emphasizing the requirement of further high-tech developments of the production and purification procedures that would allow both scaling-up and improvement of vector batch quality, necessary to human application. The scope of this review will be the state of the art in the various production methods of recombinant AAV (rAAV), delimiting their respective perimeter of application and also their main advantages and drawbacks, and thereby shedding light on the main challenges to take in the near future to bring AAV vectors more widely into the clinics.

[1]  H. Hausen,et al.  Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. , 1986, Virology.

[2]  J. Kleinschmidt,et al.  Efficient recombinant adeno‐associated virus production by a stable rep‐cap HeLa cell line correlates with adenovirus‐induced amplification of the integrated rep‐cap genome , 2000, The journal of gene medicine.

[3]  R. Buller,et al.  Characterization of adenovirus-associated virus-induced polypeptides in KB cells , 1978, Journal of virology.

[4]  A. Kamen,et al.  Production of Recombinant Adeno‐Associated Viral Vectors Using a Baculovirus/Insect Cell Suspension Culture System: From Shake Flasks to a 20‐L Bioreactor , 2008, Biotechnology progress.

[5]  Y. Schneider,et al.  Insect cell culture for industrial production of recombinant proteins , 2003, Applied Microbiology and Biotechnology.

[6]  R. Heilbronn,et al.  A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication , 1991, Journal of virology.

[7]  M. Rocchi,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Russell,et al.  Packaging Cells Based on Inducible Gene Amplification for the Production of Adeno-Associated Virus Vectors , 1998, Journal of Virology.

[9]  James M. Wilson,et al.  Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.

[10]  N. Muzyczka,et al.  The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection , 1997, Journal of virology.

[11]  M. Lock,et al.  Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  R. Kotin,et al.  Insect cells as a factory to produce adeno-associated virus type 2 vectors. , 2002, Human gene therapy.

[13]  L. Villarreal,et al.  Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.

[14]  Juan Li,et al.  A Novel Gene Expression Control System and Its Use in Stable, High-Titer 293 Cell-Based Adeno-Associated Virus Packaging Cell Lines , 2002, Journal of Virology.

[15]  B. Massie,et al.  Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy. , 2000, Human gene therapy.

[16]  M. Kay,et al.  From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. , 2003, Current gene therapy.

[17]  A. Salvetti,et al.  Improving rAAV production and purification: towards the definition of a scaleable process , 2004, The journal of gene medicine.

[18]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[19]  R. Kotin,et al.  Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles , 1997, Journal of virology.

[20]  J. Tratschin,et al.  Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function , 1984, Journal of virology.

[21]  K. Clark,et al.  Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus , 1999, Gene Therapy.

[22]  V. Choi,et al.  Production of Recombinant Adeno‐Associated Viral Vectors , 1999, Current protocols in human genetics.

[23]  H. Zentgraf,et al.  Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells , 1992, Journal of virology.

[24]  Juan Li,et al.  Feasibility of Generating Adeno-Associated Virus Packaging Cell Lines Containing Inducible Adenovirus Helper Genes , 2002, Journal of Virology.

[25]  P. Boulanger,et al.  A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  H. Avet-Loiseau,et al.  Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences , 2001, Journal of Virology.

[27]  G. Schmid.  Insect cell cultivation: growth and kinetics , 2004, Cytotechnology.

[28]  J. Casal.  Parvovirus diagnostics and vaccine production in insect cells , 2004, Cytotechnology.

[29]  D. Grimm,et al.  Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 , 1999, Gene Therapy.

[30]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[31]  R. Coffin,et al.  Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids , 2004, Gene Therapy.

[32]  A. Srivastava,et al.  Nucleotide sequence and organization of the adeno-associated virus 2 genome , 1983, Journal of virology.

[33]  D. Grimm,et al.  Subcellular compartmentalization of adeno-associated virus type 2 assembly , 1997, Journal of Virology.

[34]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[35]  Philip R. Johnson,et al.  Cell lines for the production of recombinant adeno-associated virus. , 1995, Human gene therapy.

[36]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[37]  D. Housman,et al.  Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.

[38]  U. Deuschle,et al.  Transient Transfection in Mammalian Cells , 1998 .

[39]  K. Clark,et al.  A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. , 1996, Gene therapy.

[40]  James M. Wilson,et al.  High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. , 1998, Human gene therapy.

[41]  P. Cruz,et al.  Production of core and virus-like particles with baculovirus infected insect cells. , 2002, Advances in biochemical engineering/biotechnology.

[42]  R. Samulski,et al.  Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia , 1998, Gene Therapy.

[43]  Baculovirus-insect cell interactions , 1996 .

[44]  J. Tratschin,et al.  Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells , 1985, Molecular and cellular biology.

[45]  R. Samulski,et al.  Role for highly regulated rep gene expression in adeno-associated virus vector production , 1997, Journal of virology.

[46]  J. Qiu,et al.  Alternative Polyadenylation of Adeno-associated Virus Type 5 RNA within an Internal Intron Is Governed by the Distance between the Promoter and the Intron and Is Inhibited by U1 Small Nuclear RNP Binding to the Intervening Donor* , 2004, Journal of Biological Chemistry.

[47]  Samulski,et al.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression , 1989, Journal of virology.

[48]  B. Donahue,et al.  Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors , 2004, The journal of gene medicine.

[49]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[50]  R. Heilbronn,et al.  Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. , 1998, Journal of virological methods.

[51]  D. Russell,et al.  Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2 , 1998, Journal of Virology.

[52]  R. Samulski,et al.  Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Kitts.  Construction of baculovirus recombinants , 2004, Cytotechnology.

[54]  W. Hauswirth,et al.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.

[55]  R. Samulski,et al.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication , 1987, Journal of virology.

[56]  B. Carter,et al.  Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2 , 1980, Journal of virology.

[57]  Barbara Jacko,et al.  100-liter transient transfection , 2004, Cytotechnology.

[58]  A. Benraiss,et al.  Identification of a replication‐defective herpes simplex virus for recombinant adeno‐associated virus type 2 (rAAV2) particle assembly using stable producer cell lines , 2004, The journal of gene medicine.

[59]  T. Reynolds,et al.  Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production , 1997, Journal of virology.

[60]  M. Weitzman,et al.  Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Philip R. Johnson,et al.  Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  F. Hoppe-Seyler,et al.  Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters , 1995, Journal of virology.

[63]  Wolfgang Mayer,et al.  Structure and transcription of human papillomavirus sequences in cervical carcinoma cells , 1985, Nature.

[64]  J. Trempe,et al.  A helper virus-free packaging system for recombinant adeno-associated virus vectors. , 1999, Gene.

[65]  D. Grimm,et al.  DNA helicase‐mediated packaging of adeno‐associated virus type 2 genomes into preformed capsids , 2001, The EMBO journal.

[66]  P. Fan,et al.  Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. , 1997, Human gene therapy.

[67]  D. Grimm,et al.  Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.

[68]  N. Spinner,et al.  Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  Philip R. Johnson,et al.  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.

[70]  B. Byrne,et al.  High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap , 1999, Gene Therapy.

[71]  M. Perricaudet,et al.  A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. , 2001, The Journal of general virology.

[72]  Linda Yang,et al.  Cloning and Characterization of Adeno-Associated Virus Type 5 , 1999, Journal of Virology.

[73]  J. Chiorini,et al.  Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. , 2002, Human gene therapy.

[74]  A. Salvetti,et al.  Factors influencing recombinant adeno-associated virus production. , 1998, Human gene therapy.

[75]  S. Wadsworth,et al.  Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products , 1997, Journal of virology.

[76]  T. Kanda,et al.  Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. , 2004, Virology.

[77]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[78]  J. Gray,et al.  Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. , 2002, Methods in enzymology.

[79]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  R. Snyder.  Adeno‐associated virus‐mediated gene delivery , 1999, The journal of gene medicine.

[81]  R. Mcpherson,et al.  Human cytomegalovirus completely helps adeno-associated virus replication. , 1985, Virology.